Compensation InsightHow CSL Pays
Career levels, compensation by role, equity programs (PSU, RSU, GESP), executive pay, and global operations across Australia, US, Germany, and Switzerland.
At a Glance
Career Level Hierarchy
CSL uses a global career framework. Band codes (S1–S8) are inferred from job postings, H1B data, and industry benchmarking. Scientific, commercial, and management tracks exist.
Scientist I → II → Senior → Principal → Distinguished → VP R&D
Sales Rep → Territory Manager → National Director → VP Commercial
Process Operator → Supervisor → Manager → Director → VP Manufacturing
Compensation by Level
Total compensation breakdown for Melbourne, Australia. All values in AUD.
| Level | Title | Base (Range) | Variable % | Total Comp (Range) | Equity |
|---|---|---|---|---|---|
| S1 | Graduate / Entry 0–2 yrs | A$65K – A$80K | 0% | A$78K – A$95K | GESP only |
| S2 | Associate / Analyst 1–4 yrs | A$80K – A$105K | 5% | A$95K – A$125K | GESP only |
| S3 | Scientist / Specialist 3–7 yrs | A$105K – A$140K | 12% | A$125K – A$170K | GESP; RSU eligible |
| S4 | Senior Scientist / Manager 5–10 yrs | A$140K – A$185K | 20% | A$170K – A$245K | RSU eligible |
| S5 | Principal / Senior Manager 8–14 yrs | A$185K – A$230K | 30% | A$245K – A$330K | RSU + PSU eligible |
| S6 | Associate Director 10–18 yrs | A$210K – A$270K | 40% | A$290K – A$430K | RSU + PSU |
| S7 | Director / VP 14–22 yrs | A$260K – A$350K | 55% | A$380K – A$600K | PSU significant |
| S8 | Executive (SVP / EVP / C-Suite) 18+ yrs | A$530K – A$910K | 120% | A$1.1M – A$3.0M | PSU + EPA (primary) |
Source: Glassdoor, PayScale, H1B data (h1bdata.info), CSL Annual Report FY2024, Comparably. Australian values include superannuation (12%).
Total Compensation Range by Level
Executive band (S8) excluded to avoid scale distortion.
H1B Visa Salary Data — CSL Behring LLC
US Department of Labor certified salaries for CSL Behring sponsored positions. FY2025 data.
Based on all CSL Behring LLC H1B applications certified for FY2025. King of Prussia, PA is the primary filing location.
Source: h1bdata.info, US Department of Labor LCA filings.
Variable Pay Structure
CSL operates a pay-for-performance model with STI (Short-Term Incentive) and LTI (Long-Term Incentive) components.
Variable % by Band
STI Payout History
| Year | Outcome (% of Target) | Context |
|---|---|---|
| FY2021 | 95% | COVID-19 pandemic; strong plasma demand but operational challenges |
| FY2022 | 100% | Solid operational performance; Vifor acquisition announced |
| FY2023 | 102% | Strong year; conservative payouts at only 53% of maximum opportunity |
| FY2024 | 105% | 15% NPATA growth; strong execution across divisions |
Executive STI Targets
Key Payout Insight
CSL's FY2023 average STI payout was 102% of target — only 53% of maximum opportunity. This is remarkably conservative compared to US pharma peers where near-maximum payouts are routine. The Board exercises genuine restraint on variable pay.
Equity & Share-Based Compensation
CSL spent US$169M on share-based payments in FY2024 (up from US$138M in FY2023). Equity is a core component of compensation for S4+ levels.
Active Plans
Vesting Schedule
Equity Eligibility by Level
| Level | GESP (15% discount) | RSU (Retain & Grow) | PSU (EPA) |
|---|---|---|---|
| S1–S2 | Yes | No | No |
| S3 | Yes | Occasional | No |
| S4–S5 | Yes | Yes | Selective |
| S6–S7 | Yes | Yes | Yes |
| S8 (KMP) | Yes | Yes | Yes (primary) |
PSU Performance Measures
- ROIC (Return on Invested Capital): 70% weighting
- EPS Growth: 30% weighting
- Vesting: 3-year cliff on third anniversary
- Board "Leading and Managing" modifier: ±20% up / −50% down
- Malus & clawback provisions for misconduct
Recent Grant Activity (Sep 2023)
- PSUs granted: 243,433 (executives + senior leaders)
- RSUs granted: 927,025 (qualifying employees)
- NED rights: 3,264
- Mar 2024 supplemental: 9,131 PSUs + 15,817 RSUs
- Valuation: 5-day VWAP face value allocation
ASX Insider Trades & Director Dealings
Disclosed to ASX under Corporations Act. Most disposals are sales of vested PSU/RSU shares to meet tax obligations.
| Date | Person | Role | Type | Shares | Price (A$) | Value |
|---|---|---|---|---|---|---|
| Feb 11, 2025 | Paul McKenzie | CEO (retiring) | Vesting | 45,000 | PSU vesting | Deferred equity |
| Nov 2024 | Joy Linton | CFO | Disposal | 12,000 | A$285.00 | A$3.4M |
| Oct 2024 | Andrew Schmeltz | EVP CSL Behring | Disposal | 8,500 | A$290.00 | A$2.5M |
| Sep 2024 | Brian McNamee | Chairman | Acquisition | 2,000 | A$275.00 | A$550K |
| Aug 2024 | Gordon Naylor | President Seqirus | Disposal | 5,200 | A$295.00 | A$1.5M |
| Jul 2024 | David Grubb | Non-Exec Director | Acquisition | 1,500 | A$268.00 | A$402K |
| Jun 2024 | Nai Jia Lee | Non-Exec Director | Acquisition | 800 | A$282.00 | A$226K |
| Mar 2024 | Paul McKenzie | CEO & MD | Vesting | 15,000 | PSU vesting | Deferred equity |
Share Buyback Program (FY2026)
CSL announced an A$750 million share buyback in August 2025 as part of its restructuring strategy. By December 2025, 2,551,319 shares had been repurchased. The program aims to enhance capital efficiency following the major workforce restructuring.
Source: ASX announcements, CSL Annual Report FY2024, CSL investor relations.
Executive Compensation — FY2024
CEO Transition (February 2025)
Paul McKenzie retired after only 3 years as CEO. Chairman Brian McNamee stated the Board "recognized he didn't have the skills we wanted for the future." Gordon Naylor (33-year CSL veteran, former CFO and President Seqirus) was appointed Interim CEO.
Leadership Team
Key Management Personnel fixed remuneration (local currency). Variable pay and equity not shown.
Benefits & Perks
Australia
United States
Global
- CSL Academy — Leadership and Professional Skills development platform
- Global Mobility — relocation support (visa, tax, housing, cultural training)
- Headspace/Lyra — mental health app for all employees and dependents
- Internal Mobility — cross-functional and cross-geography career moves encouraged
- 37 diversity scholarships awarded in US (2025)
- Formal recognition programs
- Community volunteering opportunities
Performance & Pay Progression
CSL uses a bi-annual performance conversation model. Values-based behaviours are non-negotiable. Annual salary review in September–October.
Promotion Timeline & Hike
Performance Framework
Glassdoor Ratings
Employee Engagement Index
74.8% (FY2024). CSL Behring rated 3.5/5 with 67% recommending to a friend. CSL Plasma rated lower at 2.9/5.
Key Nuances & Insights
CEO McKenzie's US$5.8M realized pay is ~24% of Pfizer CEO Bourla's US$24.6M. CSL's Board explicitly targets executive pay 'below the median' of global pharma peers. STI payouts average only 102% of target (53% of maximum). This conservative approach reflects Australian governance norms and CSL's science-first culture.
59% of CSL's workforce is in North America, primarily in CSL Plasma centers and the King of Prussia HQ. US roles pay 100–130% more than Australian equivalents. Adjusted for cost of living, the gap is still 40–60%. This creates internal tension between Australian HQ culture and US market expectations.
PSUs represent 47% of CEO total comp and 81% of EVP performance-related pay. Below S6, equity is limited to RSUs and the GESP (15% discount share plan). The GESP is a genuine differentiator — up to A$12K/6 months at discount — that's rare in pharma.
CSL Behring (R&D + manufacturing) has strong comp ratings (3.8/5). CSL Seqirus (vaccines) pays competitively with strong benefits. CSL Plasma has notably lower satisfaction (2.9/5 Glassdoor) and compensation ratings (3.0/5). The Vifor integration added Swiss compensation structures that create further complexity.
The largest restructuring in CSL's 100+ year history: ~4,350 jobs, 22 plasma centers closing, $700–770M cost. The CEO was also replaced. This isn't a trim — it's a strategic reset. Employee morale has been significantly impacted per Glassdoor reviews (engagement dropped, 'burnout widespread').
CSL's H1B median of $153,300 is competitive for mid-tier biotech but below Boston/SF top-tier firms. In Melbourne, senior scientists earn A$125K–160K — strong locally but modest vs US. The tradeoff: CSL offers meaningful scientific work on life-saving therapies that smaller biotechs can't match.
The planned spin-off of CSL Seqirus as an independent ASX-listed company would affect ~5,000 employees globally. The delay (due to declining US vaccination rates) adds uncertainty. Post-demerger, Seqirus employees would have different equity, benefits, and career pathways than CSL Behring/Vifor colleagues.
Founded in 1916 as Commonwealth Serum Laboratories, CSL's scientific heritage attracts talent willing to accept below-US-market comp. The graduate program (AUD $91K, only 10–14 spots) is highly competitive. Many employees cite 'saving lives' as a real motivator — not just marketing.